Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer:…

By M. Citron, D. Berry, C. Cirrincione, C. Hudis, E. Winer, W. Gradishar, N. Davidson, S. Martino, R. Livingston, J. Ingle and 11 more. Journal of Clinical Oncology, 2003

1,546 citations recorded by the source corpus.

Subfields: Cancer Research, Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/bf378c128620d25f93471b44aab2f010fa28ebeb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Charles M. Perou
2. Daniel C. Koboldt
3. Elaine R. Mardis
4. George M. Weinstock
5. Jerzy K. Kulski

In Pathology and Forensic Medicine

1. Daniel C. Koboldt

Citations in the corpus

• Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft (2010, background): “We have also validated t(1:6)(245548342;144243110) (not detected by BreakDancer), the breakpoints of which are only 4 bp and 6 bp away from the breakpoints identified on chromosomes 1 and 6 for t(1;2)(245548338;64855172) and t(2;6)(64855607;144243116), respectively (Supplementary Fig.”
• Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts (2005, background): “The use of anthracyclinebased and taxane-based therapy and more optimal endocrine therapy strategies might alter the distribution of patients, especially moving individuals from type C to type B [37-41], as experienced with the Her-2 status and adjuvant anthracycline therapy [42].”
• Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. (2005, background): “Less intensive regimens like AC or classical CMF [127, 128] are typically used for node-negative disease, while more intensive regimens such as AC or A followed by CMF [129], Canadian CEF [130], the CAF regimen [131, 132], dose-dense cyclophosphamide, doxorubicin and paclitaxel [133], FEC100 followe”
• Triple-negative breast cancer--current status and future directions. (2009, background): “However, this difference by ER status did not reach statistical significance [111].”